Clinical Trial Results: Neoplasms

Product Name: Avastin [bevacizumab]
Date of Report: To be Published
Phase: II
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.

Product Name: R1507
Date of Report: To be Published
Phase: I
A Mulitple Ascending Dose Study of R1507 in Patients With Advanced Solid Tumors.

Product Name: R1507
Date of Report: To be Published
Phase: I
A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

Product Name: R1530
Date of Report: To be Published
Phase: I
A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.

Product Name: R4733
Date of Report: To be Published
Phase: I
A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

Product Name: R547
Date of Report: To be Published
Phase: I
A Study of R547 in Patients With Advanced Solid Tumors.

Product Name: R7112
Date of Report: To be Published
Phase: I
A Study of R7112 in Patients With Advanced Solid Tumors.

Product Name: RO5083945
Date of Report: To be Published
Phase: I
A Dose-Escalation Study of RO5083945 in Patients WIth Metastatic and/or Locally Advanced Malignant EGFR+ Solid Tumors.

Product Name: Tubulin Polymerisation Inhibitor (Tub-2)
Date of Report: To be Published
Phase: I
A Study of Weekly Tubulin Polymerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.

Product Name: Tubulin Polymerisation Inhibitor (Tub-2)
Date of Report: To be Published
Phase: I
A Study of 3 Weekly Tubulerisation Inhibitor (Tub-2) in Patients With Advanced Solid Tumors.